Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Endocrine reviews

• Publication date

  2016-10-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1210/ER.2016-1078PMID 27732058
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evolving Concepts and Translational Relevance of Enteroendocrine Cell Biology.

  2016cited by this paper
• Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts.

  2016cited by this paper
• Genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

  2016cited by this paper
• In Vitro and In Vivo Investigation of the Angiogenic Effects of Liraglutide during Islet Transplantation

  2016cited by this paper
• Reappraisal of GIP Pharmacology for Metabolic Diseases.

  2016cited by this paper
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2016cited by this paper
• Insulin Plays a Permissive Role for the Vasoactive Effect of GIP Regulating Adipose Tissue Metabolism in Humans.

  2016cited by this paper
• Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways

  2016cited by this paper
• GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.

  2016cited by this paper
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  2016cited by this paper
• The blunted effect of glucose-dependent insulinotropic polypeptide in subcutaneous abdominal adipose tissue in obese subjects is partly reversed by weight loss

  2016cited by this paper
• The Cardiovascular Biology of Glucagon-like Peptide-1.

  2016influential reference
• Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization.

  2015cited by this paper
• Exendin-4 protects hindlimb ischemic injury by inducing angiogenesis.

  2015cited by this paper
• Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes

  2015cited by this paper
• PEGylated Exendin-4, a Modified GLP-1 Analog Exhibits More Potent Cardioprotection than Its Unmodified Parent Molecule on a Dose to Dose Basis in a Murine Model of Myocardial Infarction

  2015cited by this paper
• Preservation of the Blood Brain Barrier and Cortical Neuronal Tissue by Liraglutide, a Long Acting Glucagon-Like-1 Analogue, after Experimental Traumatic Brain Injury

  2015influential reference
• Deciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture

  2015cited by this paper
• Glucagon-Like Peptide-1 Receptor Activation Does Not Affect Re-Endothelialization but Reduces Intimal Hyperplasia via Direct Effects on Smooth Muscle Cells in a Nondiabetic Model of Arterial Injury

  2015cited by this paper
• Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men.

  2015cited by this paper
• Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways

  2015cited by this paper
• Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow.

  2015influential reference
• Glucose-Dependent Insulinotropic Polypeptide (GIP) Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB

  2015cited by this paper
• Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.

  2015cited by this paper
• Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

  2015cited by this paper
• Direct effect of incretin hormones on glucose and glycerol metabolism and hemodynamics.

  2015cited by this paper
• Differential effects of glucagon‐like peptide‐1 on microvascular recruitment and glucose metabolism in short‐ and long‐term insulin resistance

  2015cited by this paper
• Exendin-4 protected against critical limb ischemia in obese mice.

  2015cited by this paper
• The protective effect of GLP-1 analogue in arterial calcification through attenuating osteoblastic differentiation of human VSMCs.

  2015cited by this paper
• Evidence of Extrapancreatic Glucagon Secretion in Man

  2015cited by this paper
• Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes – a randomized, single-blinded, cross-over pilot study

  2015cited by this paper
• GLP-1 Cleavage Product Reverses Persistent ROS Generation After Transient Hyperglycemia by Disrupting an ROS-Generating Feedback Loop

  2015cited by this paper
• Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease.

  2015cited by this paper
• Gut chemosensing mechanisms.

  2015cited by this paper
• Restoration of Cerebral and Systemic Microvascular Architecture in APP/PS1 Transgenic Mice Following Treatment with Liraglutide™

  2015cited by this paper
• Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium.

  2015cited by this paper
• Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB

  2015cited by this paper
• Islet α cells and glucagon—critical regulators of energy homeostasis

  2015influential reference
• Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways

  2015cited by this paper
• Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans

  2015cited by this paper
• GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans.

  2014cited by this paper
• Glucose-dependent insulinotropic polypeptide has impaired effect on abdominal, subcutaneous adipose tissue metabolism in obese subjects

  2014cited by this paper
• Exendin-4 alleviates angiotensin II-induced senescence in vascular smooth muscle cells by inhibiting Rac1 activation via a cAMP/PKA-dependent pathway.

  2014cited by this paper
• Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells

  2014cited by this paper
• Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction

  2014influential reference
• Glucagon-Like Peptide 1 Recruits Muscle Microvasculature and Improves Insulin’s Metabolic Action in the Presence of Insulin Resistance

  2014cited by this paper
• The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential.

  2014cited by this paper
• Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism

  2014cited by this paper
• The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.

  2014influential reference
• Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells.

  2014cited by this paper
• A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis.

  2014cited by this paper
• Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors

  2014influential reference
• Characterization of [¹²⁵I]GLP-1(9-36), a novel radiolabeled analog of the major metabolite of glucagon-like peptide 1 to a receptor distinct from GLP1-R and function of the peptide in murine aorta.

  2014cited by this paper
• Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes

  2014cited by this paper
• GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

  2014influential reference
• Identification and Characterization of GLP-1 Receptor–Expressing Cells Using a New Transgenic Mouse Model

  2014cited by this paper
• Cardiovascular actions of incretin-based therapies.

  2014cited by this paper
• The effect of liraglutide on endothelial function in patients with type 2 diabetes

  2014cited by this paper
• Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2.

  2014influential reference
• GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways.

  2013cited by this paper
• Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance

  2013influential reference
• Perivascular Delivery of Encapsulated Mesenchymal Stem Cells Improves Postischemic Angiogenesis Via Paracrine Activation of VEGF-A

  2013influential reference
• Cardioprotective Effects of Exenatide in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of Exenatide Myocardial Protection in Revascularization Study

  2013cited by this paper
• GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice.

  2013influential reference
• Evaluation of the in vitro and in vivo angiogenic effects of exendin-4.

  2013cited by this paper
• GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

  2013cited by this paper
• Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes

  2013cited by this paper
• Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury in Diabetes via a cAMP/PKA/Rho-Dependent Mechanism

  2013cited by this paper
• Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus

  2013cited by this paper
• Exenatide and the treatment of patients with Parkinson's disease.

  2013cited by this paper
• The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− mouse model

  2013influential reference
• The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.

  2013influential reference
• Pharmacology, physiology, and mechanisms of incretin hormone action.

  2013influential reference
• The glucagon-like peptide-1 receptor--or not?

  2013cited by this paper
• Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways.

  2013cited by this paper
• Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow

  2012cited by this paper
• Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial

  2012cited by this paper
• Receptor identification and physiological characterisation of glucagon-like peptide-2 in the rat heart.

  2012cited by this paper
• Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

  2012cited by this paper
• Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.

  2012cited by this paper
• Glucose-dependent Insulinotropic Polypeptide (GIP) Inhibits Signaling Pathways of Advanced Glycation End Products (AGEs) in Endothelial Cells via its Antioxidative Properties

  2012cited by this paper
• Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null Mice

  2012cited by this paper
• The ghrelin gene products and exendin-4 promote survival of human pancreatic islet endothelial cells in hyperglycaemic conditions, through phosphoinositide 3-kinase/Akt, extracellular signal-related kinase (ERK)1/2 and cAMP/protein kinase A (PKA) signalling pathways

  2012cited by this paper
• The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells.

  2012cited by this paper
• The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells

  2012cited by this paper
• GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats.

  2012influential reference
• Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide–Dependent Mechanism

  2012cited by this paper
• Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.

  2012cited by this paper
• Cardiovascular biology of the incretin system.

  2012cited by this paper
• GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress.

  2012cited by this paper
• The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an “Endothelial Resistance” to Glucagon-Like Peptide 1 in Diabetes

  2011influential reference
• Glucagon-like peptide 1 protects microvascular endothelial cells by inactivating the PARP-1/iNOS/NO pathway.

  2011cited by this paper
• Glucagon-like peptide-2 (GLP-2) increases small intestinal blood flow and mucosal growth in ruminating calves.

  2011cited by this paper
• A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model

  2011influential reference
• Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury.

  2011influential reference
• Brain GLP-1 Signaling Regulates Femoral Artery Blood Flow and Insulin Sensitivity Through Hypothalamic PKC-δ

  2011cited by this paper
• Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice

  2011cited by this paper
• The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients.

  2011cited by this paper
• A Pilot Study to Assess Whether Glucagon-Like Peptide-1 Protects the Heart From Ischemic Dysfunction and Attenuates Stunning After Coronary Balloon Occlusion in Humans

  2011cited by this paper
• Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.

  2010cited by this paper

• Glucagon-like Peptide-1 Receptor Dependent Signaling in Cardiovascular Health and Disease: A Mini-review

  2026cites this paper
• Pro-healing impact of liraglutide on skin wounds in normoglycemic mice.

  2025cites this paper
• Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status

  2025cites this paper
• Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction‐associated steatotic liver disease, and other cardio‐kidney‐metabolic conditions

  2025cites this paper
• Proglucagon-derived Peptides: Human Physiology and Therapeutic Potential.

  2025cites this paper
• Molecular Insights into the Potential Cardiometabolic Effects of GLP-1 Receptor Analogs and DPP-4 Inhibitors

  2025cites this paper
• Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Arrhythmias

  2025cites this paper
• Gut Hormones in Heart Failure.

  2024cites this paper
• Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus

  2024cites this paper
• SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling

  2024cites this paper
• Unlocking the potential of glucagon-like peptide-1 receptor agonists in revolutionizing type 2 diabetes management: a comprehensive review

  2024cites this paper
• Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon

  2024cites this paper
• Advantages of glucagon-like peptide agonists in the light of prevention of cardiovascular and renal complications

  2023cites this paper
• Biology and Clinical Use of Glucagon-Like-Peptide-1 Receptor Agonists in Vascular Protection.

  2023cites this paper
• Dasiglucagon Effects on QTc in Healthy Volunteers: A Randomized, Placebo-Controlled, Dose-Escalation, Double-Blind Study

  2022cites this paper
• Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials

  2022cites this paper
• Genetic disruption of the Gipr in Apoe−/− mice promotes atherosclerosis

  2022cites this paper
• Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities.

  2022cites this paper
• Cardiovascular effects of incretins - focus on GLP-1 receptor agonists.

  2022cites this paper
• Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations

  2022cites this paper
• GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight

  2022influential citation
• Discrepancy between the Actions of Glucagon-like Peptide-1 Receptor Ligands in the Protection of the Heart against Ischemia Reperfusion Injury

  2022cites this paper
• Plaque-targeted, proteolysis-resistant, activatable and MRI-visible nano-GLP-1 receptor agonist targets smooth muscle cell differentiation in atherosclerosis

  2022cites this paper
• Empagliflozin, alone or in combination with liraglutide, limits cell death in vitro: role of oxidative stress and nitric oxide

  2021cites this paper
• Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor

  2021cites this paper
• Up-regulation of GLP-1R improved the dysfunction of late EPCs under hyperglycemia by regulating SIRT1 expression.

  2021cites this paper
• Glucagon-like Peptide-1 Receptor Agonists

  2021cites this paper
• Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors.

  2021cites this paper
• Glucagon‐like peptide‐1 receptor is expressed in human and rodent testis

  2020cites this paper
• Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms

  2020cites this paper
• Pancreatic Hormones

  2020cites this paper
• Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study

  2020cites this paper
• The gut hormone receptor GIPR links energy availability to the control of hematopoiesis

  2020cites this paper
• Glucagon like peptide 1 and glucose-dependent insulinotropic polypeptide stimulate the release of substance P from TRPV1 and TRPA1 expressing sensory nerves.

  2020cites this paper
• Exenatide, metformin, or both for prediabetes in PCOS: A randomized, open-labeled, parallel-group controlled study.

  2020cites this paper
• High‐Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta‐Adrenoceptor Blockade: A Randomized Clinical Trial

  2020cites this paper
• Pancreatic Blood Flow with Special Emphasis on Blood Perfusion of the Islets of Langerhans.

  2019cites this paper
• Incretin therapy for diabetes mellitus type 2.

  2019cites this paper
• GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells

  2019cites this paper
• Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms.

  2019influential citation
• Suramin combined with ginsenoside Rg3 alleviates cascular lesions and adventitial inflammation in venous allografts

  2019cites this paper
• Involvement of Vascular Endothelial Cells in the Anti-atherogenic Effects of Liraglutide in Diabetic Apolipoprotein E-null Mice

  2019cites this paper
• Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS

  2019cites this paper
• Over 1,000 genetic loci influencing blood pressure with multiple systems and tissues implicated.

  2019cites this paper
• Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People

  2019cites this paper
• Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients

  2019cites this paper
• Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure

  2019cites this paper
• GLP-1 Receptor Expression Within the Human Heart

  2018cites this paper
• Inflammageing and metaflammation: The yin and yang of type 2 diabetes.

  2018cites this paper
• Аналог глюкагоноподобного пептида-1 лираглутид (Саксенда®): механизм действия, эффективность в лечении ожирения

  2018cites this paper
• Treatment with GLP-1 Receptor Agonists

  2018cites this paper
• Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders

  2018cites this paper
• Glucose-Dependent Insulinotropic Polypeptide Suppresses Peripheral Arterial Remodeling in Male Mice.

  2018cites this paper
• Glucagon‐like receptor 1 agonists and DPP‐4 inhibitors: Anti‐diabetic drugs with anti‐stroke potential

  2017cites this paper
• Discovery, characterization, and clinical development of the glucagon-like peptides.

  2017cites this paper
• Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

  2017cites this paper
• Glucagon‐like peptide‐1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men

  2017cites this paper
• Diabetic retinopathy: new therapeutic perspectives based on pathogenic mechanisms

  2017cites this paper
• Intestinal Incretins and the Regulation of Bone Physiology.

  2017cites this paper
• World Journal of Diabetes

  year unknowncites this paper